Matthew Onaitis

Matthew Onaitis

Director of Finance/CFO at MAINSTAY MEDICAL INTERNATIONAL
55 year
Health Technology
Consumer Services
Health Services

Profile

Matthew W.
Onaitis
is currently Director at Snp Bio, Inc. and Stratify Genomics, Inc. He serves as Chief Financial Officer at Mainstay Medical International Ltd. since 2018 and at Mainstay Medical Holdings Plc.
Formerly, Mr. Onaitis was Director-Legal Affairs at Elan Corp.
Plc from 2004 to 2005, Associate General Counsel at Biogen, Inc. in 2006, Secretary, Senior Vice President & General Counsel at Somaxon Pharmaceuticals, Inc. from 2010 to 2013, Secretary & General Counsel at Trius Therapeutics, Inc. in 2013, Secretary & General Counsel at Ignyta, Inc. from 2014 to 2016, and CFO, Secretary, CAO & General Counsel at Cidara Therapeutics, Inc. in 2018.
Education includes an undergraduate degree from Carnegie Mellon University in 1993 and a graduate degree from Stanford Law School in 1998.

Matthew Onaitis active positions

CompaniesPositionStart
MAINSTAY MEDICAL INTERNATIONAL Director of Finance/CFO 20/08/2018
Snp Bio, Inc.
Director/Board Member -
Director/Board Member -
Director of Finance/CFO -

Former positions of Matthew Onaitis

CompaniesPositionEnd
CIDARA THERAPEUTICS Director of Finance/CFO 17/08/2018
IGNYTA INC General Counsel 01/06/2016
General Counsel 01/12/2013
General Counsel 01/03/2013
BIOGEN INC. Corporate Officer/Principal 01/05/2006
See the detail of Matthew Onaitis's experience

Training of Matthew Onaitis

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

77

1st degree connections

12

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies12

Health Technology

Health Technology

Consumer Services

Health Technology

Health Technology

Health Technology

Health Technology

Consumer Services

Health Technology

Snp Bio, Inc.

Health Services

Finance

  1. Stock Market
  2. Insiders
  3. Matthew Onaitis
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!